Science News
from research organizations

Pancreatitis reduced by nearly 50% after gene therapy to treat lipoprotein lipase deficiency

Date:
November 8, 2016
Source:
Mary Ann Liebert, Inc., Publishers
Summary:
Over a 6-year period, patients with the genetic disease lipoprotein lipase deficiency (LPLD) who received a single gene therapy treatment of alipogene tiparvovec had a marked reduction in the severity and frequency of pancreatitis. No cases of severe pancreatitis and only one admission to the intensive care unit for an LPLD-related abdominal event were reported in the study.
Share:
FULL STORY

Over a 6-year period, patients with the genetic disease lipoprotein lipase deficiency (LPLD) who received a single gene therapy treatment of alipogene tiparvovec had a marked reduction in the severity and frequency of pancreatitis. No cases of severe pancreatitis and only one admission to the intensive care unit for an LPLD-related abdominal event were reported in the study published in Human Gene Therapy.

Daniel Gaudet and coauthors from Université de Montréal, Canada, Academic Medical Center and uniQure BV (Amsterdam, the Netherlands), Chiesi Farmaceutici (Parma, Italy), Beaujon Hospital, Denis Diderot University (Paris, France), University Hospital of North Midlands (U.K.), and Erasmus Medical Centre (Rotterdam, the Netherlands) present their findings in the article entitled "Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis."

The researchers assessed LPLD-related acute abdominal events that required hospital care in a small group of patients treated with a single dose of the gene therapy product Glybera®. The results support an association between gene therapy for this rare genetic disease and overall reductions in healthcare costs and resource utilization.

"As gene therapy moves forward into the mainstream of medicine, it will be critical to define the evidence of its benefit to patients with specific diseases," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "This work with alipogene tiparvovec provides an evidence-based guideline for its use in patients with LPLD going forward."


Story Source:

Materials provided by Mary Ann Liebert, Inc., Publishers. Note: Content may be edited for style and length.


Journal Reference:

  1. Daniel Gaudet, Erik S. Stroes, Julie Méthot, Diane Brisson, Karine Tremblay, Sophie J. Bernelot Moens, Giorgio Iotti, Irene Rastelletti, Diego Ardigo, Deyanira Corzo, Christian Meyer, Marc Andersen, Philippe Ruszniewski, Mark Deakin, Marco J. Bruno. Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. Human Gene Therapy, 2016; DOI: 10.1089/hum.2015.158

Cite This Page:

Mary Ann Liebert, Inc., Publishers. "Pancreatitis reduced by nearly 50% after gene therapy to treat lipoprotein lipase deficiency." ScienceDaily. ScienceDaily, 8 November 2016. <www.sciencedaily.com/releases/2016/11/161108123854.htm>.
Mary Ann Liebert, Inc., Publishers. (2016, November 8). Pancreatitis reduced by nearly 50% after gene therapy to treat lipoprotein lipase deficiency. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2016/11/161108123854.htm
Mary Ann Liebert, Inc., Publishers. "Pancreatitis reduced by nearly 50% after gene therapy to treat lipoprotein lipase deficiency." ScienceDaily. www.sciencedaily.com/releases/2016/11/161108123854.htm (accessed May 23, 2017).

RELATED STORIES